IGF2BP2 and acute lymphoblastic leukemia: Though low dosage of JX5 (25 μM) showed the potential therapeutic effect of inhibition in T-ALL similar to that of IGF2BP2 interference (Fig. 6C), it only reduced half of T-ALL cells viability after 4 days treatment, which might provide a slight possibility of surviving T-ALL to evolve into an IGF2BP2-resistant phenotype.